Company intelligence / Profile preview

Morphotek

Exton, Pennsylvania, United Statesmorphotek.com ↗

Ownership: Private
Development stage: Other

Overview

Morphotek developed novel monoclonal antibodies and protein therapeutics using proprietary gene evolution technologies. The company’s MORPHODOMA® technology enabled rapid creation of high-titer cell lines for scalable manufacturing. It focused on oncology and partnered with major institutions like the National Cancer Institute to develop new antibody drugs targeting unmet needs such as pancreatic cancer. After its acquisition by Eisai Co., Ltd., Morphotek continued developing its pipeline within the parent organization.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Protein therapeuticsTumor-targeting peptides
Industry: Biotech

Partnerships

National Cancer Institute (NCI)Novo NordiskPivotal BioSciencesMicromet/National Institutes of Health/Cancer Innovations Inc.

Beyond the preview

Go deeper on Morphotek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphotek.